Sequential Immunochemotherapy Treatment with Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tipiracil Plus Bevacizumab in Refractory Mismatch-repair-proficient (pMMR) or Microsatellite-stable (MSS) Metastatic Colorectal Cancer

NCT06522919 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer Metastatic
Microsatellite Stable Colorectal Carcinoma
Refractory Mismatch-repair-proficient (pMMR) Metastatic Colorectal Cancer

Interventions

BIOLOGICAL: Autologous Dendritic Cell (DC) Vaccine

Sponsor

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS